newsfilter
← Latest News
PR Newswire·

RegeneRx Provides Regulatory Update Regarding RGN-259

ROCKVILLE, Md., March 2, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration has posted information released by HLB Therapeutics